|本期目录/Table of Contents|

[1]禹乐综述,余英豪审校.非小细胞肺癌胸腔积液EGFR突变检测方法的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2017,19(04):380-384.[doi:10.3969/j.issn.1672-271X.2017.04.012]
点击复制

非小细胞肺癌胸腔积液EGFR突变检测方法的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年04期
页码:
380-384
栏目:
综述
出版日期:
2017-08-10

文章信息/Info

Title:
-
作者:
禹乐1综述; 余英豪2审校
作者单位：1.363000漳州,解放军第175医院病理科；2.350025福州，南京军区福州总医院病理科
Author(s):
-
关键词:
肺癌; 胸腔积液; 细胞学; EGFR基因
Keywords:
-
分类号:
R734.2
DOI:
10.3969/j.issn.1672-271X.2017.04.012
文献标志码:
A
摘要:
非小细胞肺癌（NSCLC）是肺癌中最常见的组织学类型。目前以吉非替尼为代表的EGFR酪氨酸激酶抑制剂(EGFR-TKIs)是治疗NSCLC最重要的基因靶向治疗药物。用于检测EGFR基因突变的标本来源主要是肿瘤手术切除组织，但是对于心肺功能较差无法耐受手术或已经失去手术机会的NSCLC晚期患者，肿瘤标本的获得往往比较困难。恶性胸腔积液是晚期NSCLC患者常见的症状，获取比较容易。因此利用胸腔积液进行EGFR基因突变检测是目前研究的一个热点，文章现就EGFR与NSCLC关系、EGFR基因突变检测方法 、肺癌患者胸腔积液中EGFR基因突变情况等进行综述。
Abstract:
-

参考文献/References:

[1]Torre LA, Bray F，Sierl RL, et al. Global cancer statistics[J]. CA Cancer J Clin， 2015,65(2):87-108.
[2］Jemal A，Jemal A, Siegel R, et al. Cancer statistics [J]. CA Cancer J Clin， 2007,57(1):43-66.
[3］周小林. CRP和Alb与初诊断的非小细胞肺癌临床病理特征联系及预后价值分析[J]. 东南国防医药，2016,18(5):489-492.
[4］许阳,陈良安,田庆,等. 表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌一线治疗中的应用[J]. 中国肺癌杂志,2010,13(1):48-53.
[5］Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009,361(10): 947-957.
[6］张缨,李祥周,周瑜,等.非小细胞肺癌胸腔积液细胞块分子病理检测胡意义[J]. 医学研究生学报,2013,26(8):829-832.
[7］Cao C, Lu S, Sowa A, et al. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs [J]. Cancer Letters,2008,266(2):249-262.
[8］Sibilia M，Kroismayr R，Lichtenberger BM，et al.The epidermal growth factor receptor: from development to tumorigenesis [J]. Differentiation，2007,75(9):770－787.
[9］Ciardiello F, Tortora G. EGFR antagonists in cancer treatment [J]. N Engl J Med, 2008, 358(11): 1160-1174.
[10］王晓萍,丰俊东.放射治疗与分子靶向药物在肿瘤中的联合应用[J]. 东南国防医药,2008,10(4):20-21.
[11］Paez JG, Jnne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004,304(5676):1497-1500.
[12］Mak RH, Doran E, Muzikansky A,et al. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC[J]. Oncologist, 2011, 16(6):886-895.
[13］Luo YH, Wu CH, Wu WS, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs[J]. J Thorac Oncol,2012, 7(2):299-305.
[14］Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8):735-742.
[15］Chan SK，Gullick WJ，Hill ME． Mutations of the epidermal growth factor receptor in Non-small-cell lung cancer search and destroy[J]．Eur J Cancer，2006，42(1):17-23.
[16］Mok TS, Wu YL, Thongprasert S, et al. Gefitinibor carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009,361(10):947-957.
[17］Ren S, Kuang P, Zheng L, et al. Analysis of driver mutations in female non-smoker asian patients with pulmonary adenocarcinoma[J]. Cell Biochem Biophys, 2012, 64(2):155-160.
[18］Tiseo M, Gelsomiaino F, Boggni D, et al. EGFR and EML 4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations[J]. Lung Cancer, 2011,71(2):241-243.
[19］Pao W，Miler V，Zakowski M，et al. EGF receptor gene mutations are common in lung cancers from‘never smokers’and are associated with sensitivity of tumors to gefitinib and erlotinib[J]．Proc Natl Acad Sci USA，2004，101(36): 13306-13311.
[20］Lynch TJ,Bell DW,Sordella R,et al. Activating mutations in the epidermalgrowth factor receptor underlying responsiveness of non-small cell lung can-cer to ge tinib[J]. N Engl J Med,2004,350(21):2129-2139.
[21]Paez JG,Janne PA,Lee JC,et al. EGFR mutations in lung canaer:correla-tion with clinical response to ge tinib therapy[J]. Science,2004,304(5676):1497-1500.
[22]Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD - 1839(Iressa), an epidermal growth factor receptor - selective tyrosine kinase inhibitor[J]. Clin Cancer Res,2000,6(5):2053.
[23]Zhu JQ,Zhong WZ,Zhang GC,et al. Better survival with EGFR exon 19than exon 21 mutations in ge tinib-treated non-small cell lung cancer pa-tients is due to differential inhibition of downstream signals[J]. Cancer Lett,2008,265(2):307-317.
[24]D′Amico TA,Aloia TA,Moore MB,et al. Molecular biologic substaging ofstage I lung cancer according to gender and histology[J]. Ann Thorac Surg, 2000, 69 (3):882-886.
[25]Asano H, Toyooka S, Tokumo M,et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay[J]. Clin Cancer Res,2006,12(1):43-48.
[26]Endo K, Fonishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay[J]. Lung Cancer, 2005, 50(3):375-384.
[27]Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies [J]. Bmc Cancer, 2008, 8: 142-154.
[28]Newton CR,Graham A, Heptinstall LE,et al. Analysis of any point mutation in DNA. The amplification refractory mutation system(ARMS)[J]. Nucleic Acids Res, 1989,17(7):2503-2516.
[29]王璇,时姗姗,马恒辉,等. 非小细胞肺癌表皮生长因子受体基因突变的结果分析[J]. 东南国防医药，2012,14(5):387-389.
[30]潘羡心，孟加榕，郭以河，等. HRM方法检测肺腺癌患者癌性胸水上清液EGFR基因突变的临床意义[J]. 现代肿瘤医学,2014,22(10):2332-2335.
[31]郭以河，潘羡心，孟加榕,等. 恶性胸腔积液不同成分DNA提取结果比较分析[J]. 中国煤炭工业医学杂志,2015,18(2):280-283.
[32]郭以河，孟加榕,张闽峰,等. 一种快速提取恶性胸水中肿瘤细胞DNA的方法[J]. 现代肿瘤医学,2013,21(12):2833-2834.
[33]赵瑾，田俏梅，吴白平.非小细胞肺癌胸腔积液与小活检标本中EGFR基因突变检测的比较[J]. 黑龙江医药科学2014,37(3)109-110.
[34]Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients[J]. Cancer SCI, 2006,97(7):642-648.
[35]Soh J，Toyooka SK，Asano H,et al. Usefulness of EGFR mutation screening in pleural fleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer[J]. Int J Aancer, 2006,119(10):2353-2358.
[36]Zhang X,Zhao Y, Wang M,et al. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer[J]. Lung Cancer,2008,60(2):175-182.
[37]丁丽,张萍,武晓楠,等. 非小细胞肺癌患者胸腔积液肿瘤细胞基因突变检测及其在治疗中的价值[J]. 河北医科大学学报,2011,32(1):1-4.
[38]谢强,陈群,石琴,等. 内科胸腔镜非小细胞肺癌活检标本及胸腔积液中EGFR基因突变检测[J]. 临床与实验病理学杂志,2013,29(8):881-883.
[39]魏冰,马杰,马智勇,等. 肺腺癌患者恶性胸腔积液中EGFR 突变状况分析科[J]. 临床与实验病理学杂志,2012,28(3)323-326.
[40]尹迎春,王新美,李良,等. 非小细胞肺癌胸腔积液细胞蜡块检测EGFR与K-ras基因突变和EML4-ALK融合基因及其临床病理特征[J]. 中国胸心血管外科临床杂志,2015,22(9):870-874.
[41]Hung MS, Lin CK, Leu SW, et al. Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions[J]. Chang Gung Med J, 2006, 29 (4):373-379.
[42]Tsai TH,Su KY,Wu SG,et al. RNA is favourable for analyzing EGFR mutations in malignant pleural effusion of lung caner[J]. Eur Respir J,2012,39(3):677-684.
[43]邢舴,呼群,苏乌云,等. 非小细胞肺癌免疫组化指标的表达与EGRF基因突变的相关性[J]. 医学研究生学报,2017,30(3):275-278.

相似文献/References:

[1]许德兵,胡 燕,王 颖,等.女性肺癌95例临床分析[J].医学研究与战创伤救治(原医学研究生学报),2013,15(03):255.[doi:10.3969/j.issn.1672-271X.2013.03.016]
　XU De-bing,HU Yan,WANG Ying,et al.Clinical analysis of 95 cases of female lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(04):255.[doi:10.3969/j.issn.1672-271X.2013.03.016]
[2]时维东,陶小红,丁汇清,等.女性肺癌的影像诊断与临床对照分析[J].医学研究与战创伤救治(原医学研究生学报),2013,15(01):35.
　SHI Wei-dong,TAO Xiao-hong,DING Hui-qing,et al.Imaging diagnosis and clinical comparative study of lung cancer in female[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(04):35.
[3]郑大东,钟 勇.肿瘤标志物及PET未见异常的肺癌1例[J].医学研究与战创伤救治(原医学研究生学报),2012,14(01):70.
[4]王 璇,时姗姗,马恒辉,等.非小细胞肺癌表皮生长因子受体基因突变的结果分析[J].医学研究与战创伤救治(原医学研究生学报),2012,14(05):387.
　WANG Xuan,SHI Shan-shan,MA Heng-hui,et al.Respective analysis of EGFR mutations in non-small cell lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(04):387.
[5]王兴元,杨善进,顾亚兰,等.胸腔植入细管治疗良恶性胸腔积液452例[J].医学研究与战创伤救治(原医学研究生学报),2009,11(06):545.
[6]周 源,汪 栋,张传生,等.肺癌患者术前病理诊断的临床意义[J].医学研究与战创伤救治(原医学研究生学报),2008,10(02):97.
　ZHOU Yuan,WANG Dong,ZHANG Chuan-sheng,et al.Clinical significance of preoperatively pathological diagnosis of lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(04):97.
[7]庄聪文,翁向群,程先进,等.胺碘酮转复肺癌术后室上性心律失常的 疗效分析[J].医学研究与战创伤救治(原医学研究生学报),2008,10(04):252.
　ZHUANG Cong-wen,WENG Xiang-qun,CHENG Xian-jin,et al.Analysis of amiodarone therapy for supraventricular arrhythmias after operation in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(04):252.
[8]许德兵,吴凌云综述,宋 勇审校.miRNA与肺癌关系的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2014,16(01):73.
[9]艾书跃,杨凤娇,袁 梅,等.原发性肺癌原发灶PET/CT征象与发生淋巴结及远处转移的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):138.[doi:10.3969/j.issn.1672-271X.2015.02.008]
　AI Shu-yue,YANG Feng-jiao,YUAN Mei,et al.Correlation between the PET/CT signs of primary lung cancer and metastases[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):138.[doi:10.3969/j.issn.1672-271X.2015.02.008]
[10]肖鑫武,孙文逵,刘亚芳,等.超声支气管镜引导下的经支气管镜针吸活检术在纵隔及肺部病变诊疗中的应用价值[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):239.[doi:10.3969/j.issn.1672-271X.2015.03.005]
　XIAO Xin-wu,SUN Wen-kui,LIU Ya-fang,et al.The application value of endobronchial ultrasound-guided transbronchial needle aspiration in diagnosis and treatment of mediastinal and pulmonary diseases[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):239.[doi:10.3969/j.issn.1672-271X.2015.03.005]
[11]许德兵,潘士勇,史兆荣,等.肺癌合并胸腔积液172例临床分析[J].医学研究与战创伤救治(原医学研究生学报),2008,10(02):107.
　XU De-bing,PAN Shi-yong,SHI Zhao-rong,et al.Clinical analysis of 172 cases of malignant pleural effusion with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(04):107.

备注/Memo

备注/Memo:
基金项目：南京军区医药卫生科研基金(10MA076);南京军区联勤第十八分部青年培育项目（18FBQN2015008）;福建漳州市科技局资助项目(Z2011066);解放军第175医院科研基金(16Y020)
更新日期/Last Update: 2017-07-20